Half Yearly Report

July 30, 2015

July 30, 2015 – Shire plc (the “Group”) (LSE: SHP, NASDAQ: SHPG), in accordance with the Financial Conduct Authority's Disclosure Rules and Transparency Rules, is publishing today its Half Yearly Report for the six months ended June 30, 2015.

It should be noted that on July 23, 2015 the Group previously announced its results in respect of the same period.

For further information please contact:

Investor Relations

 

 

Sarah Elton-Farr

seltonfarr@shire.com

+44 1256 894157

Media

 

 

Michele Galen

mgalen@shire.com

+1 781 482 1867

Brooke Clarke

brclarke@shire.com

+44 1256 894 829

Download the PDF for the full release

NOTES TO EDITORS

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.

www.shire.com